Post by HAYA Therapeutics

✈️ We are participating in the BIO International Convention 2026 (#BIO2026) in San Diego! We are thrilled to announce that HAYA’s CEO, Samir Ounzain, will join peers and pioneers from Eli Lilly and Company, NewLimit, and Junevity for the panel session: “Translating Longevity Biology into Therapeutics for Age-Related Diseases.” The longevity landscape has reached a mature inflection point, shifting away from broad, systemic approaches toward a rigorous era of targeted, disease-specific execution. HAYA’s distinct approach lies in unlocking the untapped architecture of the regulatory genome. By targeting the functional components driving disease causality, we are advancing RNA-guided therapies aimed to reprogramming disease-driving cell states and restoring cellular health. This unique approach to cellular reprogramming, powered by our proprietary platform, positions HAYA as a key contributor to the healthspan field, with a scalable pipeline focused on addressing high-burden, common, chronic, and age-related conditions. We look forward to a fruitful discussion on how the field can safely advance the path toward novel therapeutic solutions focused on delivering a lasting impact for patients. 🤝 📅 Join us for this breakout session:  Date: June 24th, 2026  Time: 1:45–2:45 PM  Location: San Diego Convention Center, Room 31C ➡️ Learn more: https://lnkd.in/gB6gSbHy Let’s connect in San Diego! #BIO2026 #Longevity #Aging #RNAMedicines #CellularReprogramming #Healthspan #PrecisionMedicine #RegulatoryGenome #NoncodingGenome